Boehringer Ingelheim India has announced a strategic distribution partnership with Vvaan Lifesciences Private Limited to expand the reach of its pet parasiticide portfolio across India. This collaboration is a key initiative under Boehringer Ingelheim India's Animal Health Accelerated Growth Plan (AGP) and represents a significant milestone in the company’s efforts to enhance customer value and access in the growing animal health sector.

India’s pet healthcare market is estimated to be worth around EUR 115 million. According to Boehringer Ingelheim India’s internal analysis, metropolitan and Tier 1 cities account for approximately 60% of the total market revenue, while Tier 2 and smaller cities contribute the remaining 40%. Recognizing the untapped potential in these underserved areas, this partnership seeks to leverage Vvaan Lifesciences’ expertise and strong presence in Tier 2 cities to extend the reach of Boehringer Ingelheim’s pet portfolio.

The collaboration is designed to address the rising demand in smaller cities and mini metros, thereby expanding Boehringer Ingelheim’s customer base and improving veterinary care standards across the country. As part of the ongoing mission to advance animal health, this partnership will bring high-quality pet medications and parasiticides to communities that have traditionally struggled with limited access to such products.

Dr. Vinod Gopal, Country Head – Animal Health at Boehringer Ingelheim India, highlighted the importance of this collaboration: “At Boehringer Ingelheim, our commitment is to make innovative, high-quality medications accessible to all, irrespective of geographical boundaries. We understand the unique challenges faced by pet parents and vets in non-metro and rural areas in accessing quality healthcare. Our partnership with Vvaan Lifesciences marks a critical step in bridging this gap, allowing us to effectively reach and serve underserved markets, thereby enhancing the health and well-being of pets in these regions”.

Dr. Maneesh Jain, Director & CEO of Vvaan Lifesciences, expressed optimism about the collaboration, stating, “We are thrilled to partner with Boehringer Ingelheim. Our deep-rooted presence in Tier 2 cities, combined with Boehringer Ingelheim’s innovative pet parasiticide products, will greatly enhance the availability and quality of pet healthcare across India. Together, we aim to make a positive impact on the lives of pets and their owners in these regions, with the strong support of veterinarians”.

The partnership underscores Boehringer Ingelheim’s ongoing commitment to innovation and excellence in animal health. By collaborating with Vvaan Lifesciences, the company aims to reinforce its position as a leader in the pet healthcare sector while driving progress in veterinary care across the nation.